CytarabineThird Party Manufacturing in India

Cytarabine works by disrupting DNA synthesis and repair inside rapidly dividing cancer cells, ultimately halting their growth and inducing cell death.

As a cell cycle phase-specific antineoplastic agent, Cytarabine acts selectively during the S-phase of cell division. Once inside the cell, it is phosphorylated by cellular kinases into its active form, cytarabine triphosphate. This active metabolite competes directly with deoxycytidine triphosphate to bind to and inhibit DNA polymerase, the primary enzyme responsible for synthesizing new DNA. When cytarabine is incorporated into the growing DNA strand, its altered arabinose sugar component prevents further nucleotide addition, resulting in immediate chain termination. This prevents both DNA replication and subsequent repair mechanisms.

Unlike general chemotherapy agents, Cytarabine targets the S-phase of the cell cycle, making it exceptionally potent against rapidly multiplying malignant hematological cells. It is widely recognized as a cornerstone agent in remission induction therapy for acute leukemias and other lymphocytic neoplasms.

Therapeutic Uses

Cytarabine is prescribed for the treatment of:

• Acute Myeloid Leukemia (AML): Used as a primary induction and consolidation chemotherapy agent to achieve and maintain remission in adult and pediatric patients.
• Acute Lymphoblastic Leukemia (ALL): A crucial component in combination chemotherapy regimens for lymphatic leukemia.
• Meningeal Leukemia: Administered intrathecally to treat or prevent leukemic infiltration into the central nervous system.
• Non-Hodgkin's Lymphomas: Utilized in salvage and consolidation therapy protocols for high-grade lymphatic cancers.
• Other Malignancies: Frequently used in salvage protocols for refractory and relapsed lymphoid neoplasms.

Why Manufacturers Choose Cytarabine

Cytarabine is a critical antineoplastic agent with high global clinical value, listed on the WHO Model List of Essential Medicines. As a first-line treatment for acute leukemia, it has stable, non-cyclical demand from national oncology centers, specialized hospital groups, and government tenders.

For contract manufacturers, Cytarabine presents a high-barrier-to-entry opportunity. Producing sterile cytostatic injectables requires specialized oncology blocks equipped with high-containment aseptic lines to protect operators and eliminate cross-contamination risks. Sourcing from a WHO-GMP certified manufacturer in India allows pharmaceutical companies to offer reliable, cost-effective Cytarabine injections in various concentrations (100mg, 500mg, and 1000mg vials) that strictly comply with international IP, BP, and USP pharmacopoeial specifications.

This makes Cytarabine one of the most sought-after oncology molecules for third party manufacturing in India, with consistent demand from specialized oncology clinics and export-oriented distributors.